|
1) Freeman RV, Otto CM. Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. Circulation. 2005; 111: 3316-26
|
|
|
|
2) Rajamannan NM, Otto CM. Targeted therapy to prevent progression of calcific aortic stenosis. Circulation. 2004; 110: 1180-2
|
|
|
|
|
|
3) Osman L, Yacoub MH, Latif N, et al. Role of human valve interstitial cells in valve calcification and their response to atorvastatin. Circulation. 2006; 114: I547-52
|
|
|
|
|
|
4) Rajamannan NM, Bonow RO, Rahimtoola SH. Calcific aortic stenosis: an update. Nat Clin Pract Cardiovasc Med. 2007; 4: 254-62
|
|
|
|
|
|
5) Rosenhek R. Statins for aortic stenosis. N Engl J Med. 2005; 352: 2441-3
|
|
|
|
|
|
6) Cowell SJ, Newby DE, Prescott RJ, et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med. 2005; 352: 2389-97
|
|
|
|
|
|
7) Rajamannan NM, Subramaniam M, Springett M, et al. Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve. Circulation. 2002; 105: 2660-5
|
|
|
|
|
|
8) Drolet MC, Arsenault M, Couet J. Experimental aortic valve stenosis in rabbits. J Am Coll Cardiol. 2003; 41: 1211-7
|
|
|
|
|
|
9) Drolet MC, Roussel E, Deshaies Y, et al. A high fat/high carbohydrate diet induces aortic valve disease in C57BL/6J mice. J Am Coll Cardiol. 2006; 47: 850-5
|
|
|
|
|
|
10) Jian B, Jones PL, Li Q, et al. Matrix metalloproteinase-2 is associated with tenascin-C in calcific aortic stenosis. Am J Pathol. 2001; 159: 321-7
|
|
|
|
|
|
11) Hanada K, Vermeij M, Garinis GA, et al. Perturbations of vascular homeostasis and aortic valve abnormalities in fibulin-4 deficient mice. Circ Res. 2007; 100: 738-46
|
|
|
|
|
|
12) Kyndt F, Gueffet JP, Probst V, et al. Mutations in the gene encoding filamin A as a cause for familial cardiac valvular dystrophy. Circulation. 2007; 115: 40-9
|
|
|
|
|
|
13) Caira FC, Stock SR, Gleason TG, et al. Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation. J Am Coll Cardiol. 2006; 47: 1707-12
|
|
|
|
|
|
14) Walker GA, Masters KS, Shah DN, et al. Valvular myofibroblast activation by transforming growth factor-beta: implications for pathological extracellular matrix remodeling in heart valve disease. Circ Res. 2004; 95: 253-60
|
|
|
|
|
|
15) Choi M, Stottmann RW, Yang YP, et al. The bone morphogenetic protein antagonist noggin regulates mammalian cardiac morphogenesis. Circ Res. 2007; 100: 220-8
|
|
|
|
|
|
16) Galvin KM, Donovan MJ, Lynch CA, et al. A role for smad6 in development and homeostasis of the cardiovascular system. Nat Genet. 2000; 24: 171-4
|
|
|
|
|
|
17) Timmerman LA, Grego-Bessa J, Raya A, et al. Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformation. Genes Dev. 2004; 18: 99-115
|
|
|
|
|
|
18) Garg V, Muth AN, Ransom JF, et al. Mutations in NOTCH1 cause aortic valve disease. Nature. 2005; 437: 270-4
|
|
|
|
|
|
19) Zanettini R, Antonini A, Gatto G, et al. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med. 2007; 356: 39-46
|
|
|
|
|
|
20) Schade R, Andersohn F, Suissa S, et al. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med. 2007; 356: 29-38
|
|
|
|
|
|
21) Roth BL. Drugs and valvular heart disease. N Engl J Med. 2007; 356: 6-9
|
|
|
|
|
|
22) Osman L, Chester AH, Sarathchandra P, et al. A novel role of the sympatho-adrenergic system in regulating valve calcification. Circulation. 2007; 116: I282-7
|
|
|
|
|
|
23) Shukunami C, Oshima Y, Hiraki Y. Chondromodulin-I and tenomodulin: a new class of tissue-specific angiogenesis inhibitors found in hypovascular connective tissues. Biochem Biophys Res Commun. 2005; 333: 299-307
|
|
|
|
|
|
24) Rajamannan NM, Nealis TB, Subramaniam M, et al. Calcified rheumatic valve neoangiogenesis is associated with vascular endothelial growth factor expression and osteoblast-like bone formation. Circulation. 2005; 111: 3296-301
|
|
|
|
|
|
25) Chalajour F, Treede H, Gehling UM, et al. Identification and characterization of cells with high angiogenic potential and transitional phenotype in calcific aortic valve. Exp Cell Res. 2007; 313: 2326-35
|
|
|
|
|
|
26) Yoshioka M, Yuasa S, Matsumura K, et al. Chondromodulin-I maintains cardiac valvular function by preventing angiogenesis. Nat Med. 2006; 12: 1151-9
|
|
|
|
|
|
27) Hiraki Y. [Molecular cloning of a novel cartilage-specific functional matrix, chondromodulin-I, and its role in endochondral bone formation]. Seikagaku. 1991; 63: 1449-54
|
|
|
|
|
28) Hiraki Y, Shukunami C. Angiogenesis inhibitors localized in hypovascular mesenchymal tissues: chondromodulin-I and tenomodulin. Connect Tissue Res. 2005; 46: 3-11
|
|
|
|
|